Recombinant Human PVRIG Fc Chimera Protein, CF

When Recombinant Human PVRIG Fc Chimera (Catalog #9365-PV)is immobilized at 1 μg/mL, 100 μL/well, Recombinant Human Nectin‑2/CD112 (Catalog #2229-N2) binds with an ED50 of 0.4-2.4 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human PVRIG Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human PVRIG Fc Chimera is immobilized at 1 μg/mL, 100 μL/well, the concentration of Recombinant Human
  Nectin-2/CD112 (Catalog # 2229-N2) that produces 50% of the optimal binding response is 0.4-2.4 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human PVRIG protein
  

  Human PVRIG (Thr41 & Glu43-Leu172) Accession # Q6DKI7	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q6DKI7
• N-terminal Sequence: Thr41 & Glu43
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 40 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 51-57 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in MOPS, NaCl and PEG with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in sterile water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human PVRIG Fc Chimera Protein, CF

• C7orf15
• C7orf15MGC138295
• CD112R
• MGC104322
• MGC138297
• MGC2463
• poliovirus receptor related immunoglobulin domain containing
• Poliovirus receptor-related immunoglobulin domain-containing protein
• PVRIG
• transmembrane protein PVRIG

Background

Human PVRIG (poliovirus receptor related immunoglobulin domain-containing protein), also known as CD112 receptor (CD112R), is an approximately 34 kDa single transmembrane protein in the poliovirus receptor-like protein (PVR) family (1). It is composed of a single extracellular IgV domain, one transmembrane domain, and a long intracellular domain. The intracellular domain contains two tyrosine residues, one within an ITIM-like motif that is a potential docking site for phosphatases (1). The extracellular domain sequence of human and mouse PVRIG have approximately 65% similarity. The human PVRIG gene is preferentially expressed in lymphocytes, such as T cells and NK cells, but not in monocyte derived dendritic cells (1). PVRIG functions as a cell surface receptor for Nectin-2/CD112, a cell surface protein that is widely expressed on antigen-presenting cells and tumor cells. Disrupting the PVRIG/Nectin-2 interaction enhances human T cell response, suggesting PVRIG is a novel checkpoint for human T cells (1).

1. Zhu, Y., et.al. (2016) J. Exp. Med. 213:167.

Publications for PVRIG (9365-PV)(1)

Publication using 9365-PV

• J Joung, PC Kirchgatte, A Singh, JH Cho, SP Nety, RC Larson, RK Macrae, R Deasy, YY Tseng, MV Maus, F Zhang CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity Nature Communications, 2022-03-25;13(1):1606. 2022-03-25 [PMID: 35338135] (Flow Cytometry, Human)

Bioinformatics

• Uniprot:
  • Q6DKI7()